Rare cancers, defined by their low incidence, collectively constitute nearly a quarter of all cancer diagnoses in the US and Europe, and represent a significant public health challenge. Despite their combined prevalence, research into these diseases is hindered by limited sample sizes, data fragmentation, and a lack of dedicated resources. According to Oxford Academic’s Nucleic Acids Research, the development and launch of Rare Cancer Explorer 1.0 (RaCE 1.0) directly addresses these barriers, offering the first comprehensive, open-access database and analytical platform tailored specifically for rare cancers.
Why Rare Cancers Need Special Attention
Unlike common cancers, rare cancers are highly heterogeneous and often lack large, well-annotated datasets. This leads to diagnostic delays, fewer targeted therapies, and worse overall survival. For instance, adrenocortical carcinoma (ACC) has a five-year survival rate under 35%, lagging far behind more common cancer types. Research funding, drug development, and data sharing for rare cancers have also trailed behind, making it difficult to pinpoint disease mechanisms or promising treatments.
Introducing RaCE 1.0: Bridging the Data Divide
RaCE 1.0 is designed to fill this critical gap. The platform consolidates a remarkable 5,451 samples across 13 rare solid tumor types, integrating data from 69 public datasets. Unlike existing pan-cancer resources, RaCE focuses exclusively on rare cancers, providing a one-stop shop for multi-omics analysis, visualization, and hypothesis generation.
Researchers can seamlessly access and analyze gene expression, mutations, immune infiltration, methylation patterns, drug sensitivity, and more. RaCE’s modular design includes:
- Meta-analysis for cross-dataset validation,
- Gene expression and differential expression (DEG) analysis for biomarker discovery,
- Survival analysis using both Kaplan-Meier and Cox regression models,
- Cell line dependency scoring based on CRISPR knockout data,
- Somatic mutation and methylation profiling,
- Immune microenvironment analysis using six established algorithms,
- Immunotherapy cohort survival analysis, and
- Drug response prediction using data from GDSC2, CTRP2, and PRISM.
Each module features interactive visualizations and customizable outputs, supporting researchers from data mining to publication.
Data Standardization and Analytical Rigor
A hallmark of RaCE is its robust data processing pipeline. Expression data are harmonized across RNA-seq and microarray platforms, ensuring comparability. DEGs are identified with strict controls, and enrichment analyses (GO, KEGG, GSEA, Reactome, and Disease Ontology) are built in. Clinical metadata—including stage, age, and survival endpoints—are standardized, allowing for direct clinical correlations.
For survival analysis, users can stratify patients by gene expression and visualize results as forest plots. Drug sensitivity modules leverage large-scale cell line screening data, correlating gene expression with predicted responses to hundreds of compounds—helping to prioritize potential therapies for rare tumors.
Case Study: SHISA3 in Neuroblastoma
To showcase RaCE’s utility, the team investigated SHISA3 in neuroblastoma. Differential analysis revealed SHISA3 as overexpressed in tumor versus control tissue, and survival analysis linked high SHISA3 expression to poorer patient outcomes. Further, cell line dependency scoring indicated that SHISA3 is essential for the survival of key neuroblastoma cell lines. Immune infiltration analysis showed a strong association between SHISA3 and fibroblast presence, while drug response modules highlighted several compounds (PLX4720, AZD5438, I-BET762) with potential efficacy in tumors with high SHISA3 expression. This multi-layered exploration, all within RaCE, demonstrates the platform’s capacity for rapid, integrative target discovery.
Empowering Rare Cancer Research
RaCE outpaces existing databases like GEPIA or Expression Atlas by prioritizing rare cancers and offering more comprehensive, customizable analytical tools. Its Rare Cancer Cell Line Encyclopedia module, for example, fills a crucial void by enabling functional gene validation and prioritization for lab studies.
By centralizing, standardizing, and democratizing access to rare cancer data, RaCE 1.0 lowers the barriers for researchers and clinicians everywhere. The platform’s open-access nature and user-friendly interface ensure that even those with limited computational expertise can generate actionable insights. Importantly, RaCE is designed to complement rather than replace existing resources, focusing on rare cancer-specific needs and integration.
Looking Ahead
The launch of RaCE 1.0 marks a milestone for the rare cancer research community. As more datasets become available and as the platform continues to evolve, RaCE promises to accelerate discoveries, improve biomarker and drug target identification, and inform precision medicine for patients with rare tumors—an area of oncology that has long been underserved.
Researchers can explore the platform at https://biospace.shinyapps.io/race/ or https://hiplot.com.cn/race/, and are encouraged to contribute to this growing resource. By integrating advanced analytics with rich, diverse datasets, RaCE 1.0 stands as a catalyst for collaborative, data-driven advances in rare cancer research.
